EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudie

Real-life nationwide characteristics and outcomes of small cell lung cancer over the last 20 years: Impact of immunotherapy on overall survival in a real-life setting

Lionel Falchero, Nicolas Meyer, Olivier Molinier, Faraj Al Freijat, Hervé Pegliasco, Emmanuelle Lecuyer, Luc Stoven, Laure Belmont, Sandrine Loutski, Cécile Maincent, Anne-Sophie Blanchet-Legens, Alexa Mairovitz und 5 weitere

European Journal of Cancer · 2024

DOI: 10.1016/j.ejca.2024.114277 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift European Journal of Cancer, 2024. Verfasst von Lionel Falchero und 16 weiteren Autor:innen. Beteiligte Einrichtung: Respiratory Medicine Department, Hopitaux Nord-Ouest, Villefranche-Sur-Saône, France. Electronic address: lfalchero@hno.fr. Hauptthemen laut MEDLINE: Immunotherapy, Lung Neoplasms, Small Cell Lung Carcinoma. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The KBP studies are real-life nationwide, prospective, multicenter cohort studies of patients diagnosed with primary lung cancer that have been conducted in French non-academic public hospitals each decade since 2000. METHODS: Patients were analyzed in three prospective cohorts using the same methodology. In this study, we describe and compare the characteristics and outcomes of patients with small cell lung cancer (SCLC), with a focus on treatments in the 2020 cohort. FINDINGS: 8999 patients with lung cancer were included in the 2020 cohort, of whom 1137 had SCLC. From 2000 to 2010 and 2020, the proportion of patients with SCLC decreased from 16.4 % to 13.5 % and 12.6 % respectively. Between 2000 and 2020, the proportion of women increased from 15.5 % to 35.7 %. 15.4 % of patients with SCLC had limited-stage (LS) disease and 84.6 % of patients had extensive-stage (ES) disease. The 1-year overall survival (OS) rate for all patients with SCLC increased from 34.4 % in 2000 to 38.4 % in 2020. For ES-SCLC, multivariate analysis weighted with "entropy balancing" by including age, sex, performance status, number of metastatic sites, and brain metastases indicated an improvement in median OS from 8.1 months in patients receiving chemotherapy only to 11.1 months in patients receiving chemotherapy plus immunotherapy (HR 0.62, p < 0.001). INTERPRETATION: The proportion with SCLC has decreased over time, but the proportion of women has increased. The 1-year OS rates have improved over 20 years. The KBP-2020 cohort suggests a benefit of immunotherapy on OS in patients with ES-SCLC in the real-life setting.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImmunotherapyLung NeoplasmsSmall Cell Lung CarcinomaAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedFranceProspective StudiesSurvival RateTime FactorsTreatment Outcome

Stichwörter der Autor:innen

ChemoradiotherapyChemotherapyImmunotherapyNon-academic public hospitalRadiotherapyReal-world dataSmall cell lung cancer

Autor:innen und Institutionen

  • Respiratory Medicine Department, Hopitaux Nord-Ouest, Villefranche-Sur-Saône, France. Electronic address: lfalchero@hno.fr.
  • Public Health Department, CHU de Strasbourg, GMRC, Strasbourg, France.
  • Respiratory Medicine Department, Centre Hospitalier Le Mans, Le Mans, France.
  • Respiratory Medicine Department, Hôpital Nord Franche-Comté, Belfort, France.
  • Respiratory Medicine Department, Hôpital Européen Marseille, Marseille, France.
  • Respiratory Medicine Department, Centre Hospitalier de Saint-Quentin, Saint-Quentin, France.

Zitieren

APA

Falchero, L., Meyer, N., Molinier, O., Al Freijat, F., Pegliasco, H., Lecuyer, E., Stoven, L., Belmont, L., Loutski, S., Maincent, C., Blanchet-Legens, A. S., Mairovitz, A., Meniai, F., Hominal, S., Letierce, A., Morel, H., & Debieuvre, D. (2024). Real-life nationwide characteristics and outcomes of small cell lung cancer over the last 20 years: Impact of immunotherapy on overall survival in a real-life setting. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2024.114277

Vancouver

Falchero L, Meyer N, Molinier O, Al Freijat F, Pegliasco H, Lecuyer E, et al. Real-life nationwide characteristics and outcomes of small cell lung cancer over the last 20 years: Impact of immunotherapy on overall survival in a real-life setting. European Journal of Cancer. 2024. doi:10.1016/j.ejca.2024.114277

BibTeX
@article{Falchero2024,
  author = {Falchero, Lionel and Meyer, Nicolas and Molinier, Olivier and Al Freijat, Faraj and Pegliasco, Hervé and Lecuyer, Emmanuelle and Stoven, Luc and Belmont, Laure and Loutski, Sandrine and Maincent, Cécile and Blanchet-Legens, Anne-Sophie and Mairovitz, Alexa and Meniai, Fatima and Hominal, Stéphane and Letierce, Alexia and Morel, Hugues and Debieuvre, Didier},
  title = {Real-life nationwide characteristics and outcomes of small cell lung cancer over the last 20 years: Impact of immunotherapy on overall survival in a real-life setting},
  journal = {European Journal of Cancer},
  year = {2024},
  doi = {10.1016/j.ejca.2024.114277}
}
Kostenlos starten →